Key result
Thrombophilia significantly increases the risk of venous thromboembolism during pregnancy, necessitating individualized prophylactic or therapeutic anticoagulation based on risk stratification.
Why the study?
The etiopathogenesis of obstetric complications in thrombophilia remains unclear, contributing to therapy failure and leaving open questions regarding the role of anticoagulants in preventing pregnancy loss.
Does anticoagulation therapy and screening improve pregnancy outcomes in pregnant women with thrombophilia?
Does anticoagulation therapy and screening improve pregnancy outcomes in pregnant women with thrombophilia?
This review discusses the justification for prescribing anticoagulants and evaluating their effect within thrombophilia therapeutic strategies during pregnancy.
Answers are grounded in this paper and cite their sources.
Insufficient evidence guides anticoagulation in thrombophilia pregnancies; leaves open need for RCTs before practice change.
Leading cause of death in pregnant women still remains venous thromboembolism, with an incidence of 1.4 to 4.9 per 100,000 pregnancies. A special group of inherited and acquired coagulation disorders associated with a susceptibility to thrombosis is thrombophilia. Physiological changes during the pregnancy also contribute to the occurrence thromboembolic diseases (VTE) in pregnancy. Total rate of venous thromboembolism is 100 per 100,000 pregnancies and 200 per 100,000 births. Etiopathogenesis of obstetric complications in thrombophilia is not clearly defined, which is one of the reasons for the occasional failure of therapy. In pregnancies with hereditary thrombophilia the oxidative stress is considered to be a cause of complications, similar to preeclampsia. Based on the findings so far, additional research should clarify questions regarding the anticoagulants role in pregnancy loss prevention. In this paper, we analyze the effect of the screening on pregnancy outcomes, consider the justification for the use of anticoagulation therapy in difficult situations, discuss about previous knowledge in the field and argue the use of new specific protocols. In short, we address the justification for prescribing anticoagulants and evaluation of their effect within thrombophilia therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Lončar et al. (2022) conducted a review in Thrombophilia in pregnancy. Anticoagulation therapy (LMWH, UFH) was evaluated. Thrombophilia significantly increases the risk of venous thromboembolism during pregnancy, necessitating individualized prophylactic or therapeutic anticoagulation based on risk stratification.
Synapse has enriched 10 related papers. Consider them for comparative context: